Shorla Oncology announces FDA approval for Tepylute, a novel formulation to treat breast and ovarian cancer
- Shorla Oncology received FDA approval for Tepylute, a ready-to-dilute injectable formulation for breast and ovarian cancer.
- Tepylute simplifies preparation and ensures dosing accuracy, addressing the complexities of the current lyophilized powder formulation.
- This is Shorla's third FDA-approved drug and the first in-house developed NDA.
- Tepylute is a liquid form of thiotepa, eliminating the need for reconstitution and reducing preparation errors.
- The American Cancer Society estimates over 300,000 breast cancer and 19,680 ovarian cancer diagnoses in the U.S. in 2024.
- Shorla is also awaiting FDA action on SH-201, an oral liquid treatment for leukemia, expected by November 30, 2024.
Read more
IASO Bio's GPRC5D CAR-T product RD118 receives IND approval from NMPA
- IASO Bio's RD118, a GPRC5D-targeting CAR-T therapy, received IND approval from the NMPA for treating relapsed/refractory multiple myeloma (RRMM).
- RD118 is an autologous T-cell immunotherapy targeting GPRC5D, which is highly expressed on multiple myeloma cells.
- The therapy has shown excellent in vitro cytotoxic activity and in vivo tumor suppression ability.
- An investigator-initiated clinical trial (IIT) is ongoing to evaluate the safety and efficacy of RD118 in patients with RRMM or plasma cell leukemia.
- The trial includes patients who have received at least three lines of therapy, including proteasome inhibitors and immunomodulators, and those who have had prior BCMA CAR-T therapy.
- The dose-escalation phase of the trial has completed subject enrollment and infusion, showing good safety and efficacy profiles.
Read more
Oncolytics Biotech announces productive FDA type C meeting on its metastatic breast cancer program
- Oncolytics Biotech received positive feedback from the FDA on its planned registration-enabling trial for pelareorep in HR+/HER2- metastatic breast cancer (mBC).
- The FDA supports progression-free survival as the primary endpoint and overall survival as a key secondary endpoint for the study.
- The trial will enroll patients who have failed hormonal therapy and have received no more than one line of antibody-drug conjugate (ADC) therapy.
- Oncolytics is on track to report overall survival results from the BRACELET-1 trial in HR+/HER2- mBC in the second half of 2024.
- The company aims to initiate the registration-enabling trial as a major corporate objective.
- Pelareorep has shown promising results in previous studies, including BRACELET-1, IND-213, and AWARE-1, highlighting its immune-mediated mechanism of action.
Read more
New efficacy data for non-clear cell renal cell carcinoma from KEYNOTE-B61 added to LENVIMA US label
- Eisai announced a label update for LENVIMA in the US to include clinical efficacy data for the first-line treatment of advanced non-clear cell renal cell carcinoma (nccRCC).
- The update is based on data from KEYNOTE-B61, a Phase 2, single-arm trial evaluating KEYTRUDA plus LENVIMA for the first-line treatment of adult patients with advanced nccRCC.
- KEYNOTE-B61 enrolled 160 patients and showed an objective response rate (ORR) of 51%, with a complete response rate of 8% and a partial response rate of 42%.
- The median duration of response (DOR) was 19.5 months, with no new safety signals observed.
- KEYTRUDA plus LENVIMA is now the first and only combination with data in both clear cell and non-clear cell advanced RCC in the FDA-approved label.
- The approved indication for KEYTRUDA plus LENVIMA for the first-line treatment of adult patients with advanced RCC remains unchanged.
Read more
Sirnaomics completes phase I study of STP707 for pancreatic cancer
- Sirnaomics completed a Phase I clinical study of STP707 for pancreatic cancer patients.
- The dose escalation study was conducted in 11 oncology clinics in the U.S. with six cohorts and 50 patients.
- The study aimed to evaluate the safety, tolerability, and anti-tumor activity of STP707 through intravenous infusion.
- 11 pancreatic cancer patients were enrolled, with an average of three prior lines of therapy.
- No treatment-related adverse events were reported, except for one Grade 2 infusion reaction.
- The study showed a strong safety profile and stable disease activity, warranting further research.
Read more
50% ORR: impressive clinical trial data for irpagratinib combined with atezolizumab in advanced hepatocellular carcinoma stuns ESMO-GI congress
- Abbisko Therapeutics presented new phase II clinical data at the 2024 ESMO-GI Congress.
- The combination of irpagratinib (220 mg BID) and atezolizumab showed a 50% objective response rate (ORR) in FGF19+ HCC patients.
- Strong efficacy and good safety were observed, even in patients previously treated with immune checkpoint inhibitors.
- Abbisko plans to explore dual/triple combinations with irpagratinib in earlier lines of therapy for HCC.
- Hepatocellular carcinoma (HCC) is the most common type of primary liver cancer, with FGF19-FGFR4 signaling dysregulation accounting for about 30% of cases.
- Further research and innovation are planned to better address HCC and bring hope to patients.
Read more
AbbVie receives positive CHMP opinion for epcoritamab for relapsed/refractory follicular lymphoma
- Epcoritamab (TEPKINLY) is set to become the first bispecific antibody conditionally approved as a monotherapy in the EU for relapsed/refractory follicular lymphoma (FL) and diffuse large B-cell lymphoma (DLBCL).
- The positive CHMP opinion is based on results from the Phase 1/2 EPCORE NHL-1 study, which included 128 patients with relapsed/refractory FL.
- The study showed overall and complete response data, with a safety profile similar to previous reports of epcoritamab monotherapy.
- An additional cohort of 86 patients evaluated a 3-step-up dosing schedule to reduce cytokine release syndrome (CRS), with no grade 3 or higher CRS events reported.
- Epcoritamab is being co-developed by AbbVie and Genmab, with AbbVie responsible for global commercialization.
- The European Commission decision on this indication for epcoritamab is anticipated later this year, with further international regulatory approvals being pursued.
Read more
Epcoritamab receives positive CHMP opinion for the treatment of adults with relapsed/refractory follicular lymphoma
- The European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended conditional marketing authorization for epcoritamab as a monotherapy for relapsed/refractory follicular lymphoma (FL).
- The recommendation is based on data from the Phase 1/2 EPCORE NHL-1 clinical trial, which included 128 patients with R/R FL.
- The trial showed overall and complete response rates, with common adverse reactions including CRS, injection site reactions, and neutropenia.
- An additional cohort of 86 patients evaluated an optimized step-up dosing (SUD) schedule to reduce the incidence and severity of cytokine release syndrome (CRS).
- The final decision from the European Commission on this indication for epcoritamab is expected later this year.
- Genmab and AbbVie are co-developing epcoritamab and will share commercial responsibilities in the U.S. and Japan, with AbbVie handling further global commercialization.
Read more
Cancer Therapy Evaluation Program announces availability of botensilimab for clinical studies
- The Cancer Therapy Evaluation Program (CTEP) is now accepting Letters of Intent (LOIs) for clinical studies using botensilimab.
- Botensilimab is a human Fc enhanced next-generation anti-CTLA-4 antibody developed by Agenus Inc. in collaboration with CTEP.
- CTEP will also consider supplying botensilimab for nonclinical studies.
- Agenus is committed to supporting both clinical and nonclinical research by providing botensilimab and its mouse surrogate.
- Botensilimab has shown clinical responses in phase 1 and phase 2 trials across nine metastatic, late-line cancers.
- For more information on botensilimab trials, visit clinicaltrials.gov with identifiers NCT03860272, NCT05608044, NCT05630183, and NCT05529316.
Read more
Bicara Therapeutics reports updated interim phase 1/1b data of ficerafusp alfa in 1L HPV-negative recurrent/metastatic head and neck squamous cell carcinoma
- Bicara Therapeutics presented updated interim data from its ongoing Phase 1/1b dose expansion study of ficerafusp alfa at the 3rd Hawaii Global Summit on Thoracic Malignancies.
- Ficerafusp alfa, a bifunctional antibody, showed a 64% overall response rate (ORR) and 18% complete response (CR) rate in combination with pembrolizumab in HPV-negative R/M HNSCC patients.
- The median progression-free survival (mPFS) was 9.8 months, with a favorable tolerability profile.
- The study included 39 evaluable frontline R/M HNSCC patients, with 28 being HPV-negative.
- Bicara plans to initiate a pivotal Phase 2/3 trial of ficerafusp alfa in combination with pembrolizumab in frontline R/M HNSCC excluding HPV-positive patients.
- Next steps include exploring the potential of ficerafusp alfa in other HNSCC populations and squamous cell tumor types.
Read more
